114 related articles for article (PubMed ID: 36399377)
1. Optimization of the pseudoparticle system for standardized assessments of neutralizing antibodies against hepatitis C virus.
Chumbe A; Urbanowicz RA; Sliepen K; Koekkoek SM; Molenkamp R; Tarr AW; Ball JK; Schinkel J; van Gils MJ
J Gen Virol; 2022 Nov; 103(11):. PubMed ID: 36399377
[TBL] [Abstract][Full Text] [Related]
2. A panel of hepatitis C virus glycoproteins for the characterization of antibody responses using antibodies with diverse recognition and neutralization patterns.
Chumbe A; Grobben M; Capella-Pujol J; Koekkoek SM; Zon I; Slamanig S; Merat SJ; Beaumont T; Sliepen K; Schinkel J; van Gils MJ
Virus Res; 2024 Mar; 341():199308. PubMed ID: 38171391
[TBL] [Abstract][Full Text] [Related]
3. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.
Urbanowicz RA; McClure CP; Brown RJ; Tsoleridis T; Persson MA; Krey T; Irving WL; Ball JK; Tarr AW
J Virol; 2015 Dec; 90(7):3288-301. PubMed ID: 26699643
[TBL] [Abstract][Full Text] [Related]
4. An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development.
Salas JH; Urbanowicz RA; Guest JD; Frumento N; Figueroa A; Clark KE; Keck Z; Cowton VM; Cole SJ; Patel AH; Fuerst TR; Drummer HE; Major M; Tarr AW; Ball JK; Law M; Pierce BG; Foung SKH; Bailey JR
Gastroenterology; 2022 Feb; 162(2):562-574. PubMed ID: 34655573
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.
Wasilewski LN; Ray SC; Bailey JR
J Gen Virol; 2016 Nov; 97(11):2883-2893. PubMed ID: 27667373
[TBL] [Abstract][Full Text] [Related]
6. Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp).
Bailey JR; Urbanowicz RA; Ball JK; Law M; Foung SKH
Methods Mol Biol; 2019; 1911():441-450. PubMed ID: 30593644
[TBL] [Abstract][Full Text] [Related]
7. Studies on the role of neutralizing antibodies against envelope genes in resolving HCV pseudo-particles infection.
Rafique S; Idrees M; Ali A; Iqbal M
Mol Biol Rep; 2014 Jun; 41(6):3945-50. PubMed ID: 24566682
[TBL] [Abstract][Full Text] [Related]
8. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
[TBL] [Abstract][Full Text] [Related]
9. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.
Wong JA; Bhat R; Hockman D; Logan M; Chen C; Levin A; Frey SE; Belshe RB; Tyrrell DL; Law JL; Houghton M
J Virol; 2014 Dec; 88(24):14278-88. PubMed ID: 25275133
[TBL] [Abstract][Full Text] [Related]
10. Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.
Logan M; Law J; Wong JAJ; Hockman D; Landi A; Chen C; Crawford K; Kundu J; Baldwin L; Johnson J; Dahiya A; LaChance G; Marcotrigiano J; Law M; Foung S; Tyrrell L; Houghton M
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795422
[TBL] [Abstract][Full Text] [Related]
11. A Hepatitis C Virus DNA Vaccine Encoding a Secreted, Oligomerized Form of Envelope Proteins Is Highly Immunogenic and Elicits Neutralizing Antibodies in Vaccinated Mice.
Masavuli MG; Wijesundara DK; Underwood A; Christiansen D; Earnest-Silveira L; Bull R; Torresi J; Gowans EJ; Grubor-Bauk B
Front Immunol; 2019; 10():1145. PubMed ID: 31178869
[TBL] [Abstract][Full Text] [Related]
12. N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses.
Ren Y; Min YQ; Liu M; Chi L; Zhao P; Zhang XL
Biochim Biophys Acta; 2016 Aug; 1860(8):1764-75. PubMed ID: 26278021
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies.
Stamataki Z; Coates S; Evans MJ; Wininger M; Crawford K; Dong C; Fong YL; Chien D; Abrignani S; Balfe P; Rice CM; McKeating JA; Houghton M
Vaccine; 2007 Nov; 25(45):7773-84. PubMed ID: 17919789
[TBL] [Abstract][Full Text] [Related]
14. [Development of infectious pseudo-particle harboring three subtypes hepatitis C virus glycoproteins and their application in neutralization assays].
Zhang K; Tan WJ; Deng Y; Li J; Wu XB; Ruan L
Bing Du Xue Bao; 2008 Jul; 24(4):287-94. PubMed ID: 18780632
[TBL] [Abstract][Full Text] [Related]
15. Defining Breadth of Hepatitis C Virus Neutralization.
Kinchen VJ; Bailey JR
Front Immunol; 2018; 9():1703. PubMed ID: 30116237
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype.
Tarr AW; Urbanowicz RA; Hamed MR; Albecka A; McClure CP; Brown RJ; Irving WL; Dubuisson J; Ball JK
J Virol; 2011 May; 85(9):4246-57. PubMed ID: 21325403
[TBL] [Abstract][Full Text] [Related]
17. A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.
Desombere I; Mesalam AA; Urbanowicz RA; Van Houtte F; Verhoye L; Keck ZY; Farhoudi A; Vercauteren K; Weening KE; Baumert TF; Patel AH; Foung SKH; Ball J; Leroux-Roels G; Meuleman P
Antiviral Res; 2017 Dec; 148():53-64. PubMed ID: 29074219
[TBL] [Abstract][Full Text] [Related]
18. Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.
Chmielewska AM; Naddeo M; Capone S; Ammendola V; Hu K; Meredith L; Verhoye L; Rychlowska M; Rappuoli R; Ulmer JB; Colloca S; Nicosia A; Cortese R; Leroux-Roels G; Balfe P; Bienkowska-Szewczyk K; Meuleman P; McKeating JA; Folgori A
J Virol; 2014 May; 88(10):5502-10. PubMed ID: 24599994
[TBL] [Abstract][Full Text] [Related]
19. Characterization of linear epitope specificity of antibodies potentially contributing to spontaneous clearance of hepatitis C virus.
Ahsan A; Dar S; Hassan F; Ghafoor F; Yousuf MH; Shahzad-Ul-Hussan S
PLoS One; 2021; 16(8):e0256816. PubMed ID: 34449828
[TBL] [Abstract][Full Text] [Related]
20. Determination of the human antibody response to the neutralization epitopes encompassing amino acids 313-327 and 432-443 of hepatitis C virus E1E2 glycoproteins.
Liu R; Rao H; Wang J; Xie X; Jiang D; Pan X; Zhao P; Zhang H; Wei L
PLoS One; 2013; 8(6):e66872. PubMed ID: 23826163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
